ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Argenx Announces Publication of Phase 3 ADAPT Trial Results of Efgartigimod for the Treatment of Generalized Myasthenia Gravis in The Lancet Neurology
June 17, 2021argenx (Euronext & Nasdaq: ARGX), today announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living with generalized myasthenia gravis (gMG). -
Elektrofi, Argenx Enter Collaboration and License Agreement
April 28, 2021Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, has entered into a collaboration and license agreement with argenx to explore new subcutaneous formulations for therapeutic products directed at the ...
Pharma Sources Insight January 2025
